Buprenorphine analgesia in ferrets: does buprenorphine vs no opioid analgesia reduce pain responses? — MAYBE (weak evidence) (the treatment made no difference)

In ferrets, does buprenorphine vs no opioid analgesia reduce validated pain responses after surgery?

Shelf #942 · gate-verified and displayed under the developer's blinded-trial rule

MAYBE (weak evidence) (the treatment made no difference): The only placebo-controlled test of buprenorphine antinociception in ferrets found no effect. In Desprez 2023 (PMID: 37527831; randomised, blinded, controlled, complete crossover in 14 healthy adult ferrets), single subcutaneous buprenorphine doses of 0.02 and 0.04 mg/kg did not increase forelimb withdrawal latencies to a noxious thermal stimulus compared with saline at any point over 8 hours, whereas hydromorphone 0.2 mg/kg in the same study did increase latencies significantly from 1 to 4 hours — so the assay was capable of detecting an opioid antinociceptive effect, and buprenorphine did not produce one at the doses tested. No placebo-controlled POSTOPERATIVE trial exists: the one surgical study fetched at drafting (Plunkard 2024, PMID: 39164072) compared two buprenorphine formulations against each other after ovariohysterectomy, with no untreated or placebo group, so it cannot answer buprenorphine versus no analgesia; and the route-comparison study (Ryan 2026, PMID: 41160983) is a pharmacokinetic study whose analgesia statement rests on a plasma concentration threshold taken from dogs, not on a ferret pain outcome. Design class (a) on design — randomisation and blinding are established by the carded Desprez 2023 record answering the buprenorphine-versus-saline comparison in ferrets — but the stamp stays at MAYBE (weak evidence) because that single record is one small crossover study (14 ferrets) in an induced thermal-pain model in healthy animals, using single subcutaneous doses; it does not test repeated dosing, other routes or formulations, or clinical postoperative pain, where buprenorphine might behave differently. The null is therefore a statement about the tested model and doses, not proof that buprenorphine can never relieve pain in ferrets. Drafted Nov 10, 2026 (VetMed build, topic #942); all figures from the abstracts fetched and verified at drafting.

Desprez 2023: subcutaneous buprenorphine made no difference to thermal withdrawal latencies versus saline in 14 ferrets, while hydromorphone 0.2 mg/kg increased latencies for 1-4 hours in the same crossover study

Randomized, blind, controlled, complete crossover antinociception study (record's own wording; publication types: Journal Article, Randomized Controlled Trial, Veterinary)

Who: Ferrets: 14 healthy adult ferrets (6 neutered males, 8 spayed females) in an induced-pain (thermal nociception) model — not surgical patients. In a randomized, blind, controlled, complete crossover design, every ferret received, in turn, a single subcutaneous injection of hydromorphone low dose (0.1 mg/kg), hydromorphone high dose (0.2 mg/kg), buprenorphine low dose (0.02 mg/kg), buprenorphine high dose (0.04 mg/kg), or saline solution (0.2 mL/kg). Sedation and forelimb withdrawal latency from a noxious thermal stimulation were evaluated, and behavior was recorded, for 8 hours after injection.

Result: Compared with saline, hydromorphone 0.2 mg/kg increased withdrawal latencies by an estimated 7.4 seconds (95% CI 3.2 to 11.6) at 60 minutes, 6.6 seconds (2.4 to 10.8) at 90 minutes, 6.0 seconds (1.8 to 10.2) at 120 minutes, 7.0 seconds (2.9 to 11.1) at 180 minutes and 4.5 seconds (0.5 to 8.6) at 240 minutes, all statistically significant. Hydromorphone at the lower dose and buprenorphine at EITHER dose did not increase withdrawal latencies compared with saline (the treatment made no difference). Sedation scores increased over time in a similar fashion with all treatments, including saline, and erratic dysphoric-like behaviors occurred in all groups except saline. The authors conclude that subcutaneous hydromorphone 0.2 mg/kg provided antinociception from 1 to 4 hours after injection in ferrets.

Watch out: INDUCED MODEL: the outcome is withdrawal latency from an experimental thermal stimulus in healthy ferrets, not pain after surgery — the shelf question's postoperative setting has no placebo-controlled test at all (see synthesis). Only single subcutaneous doses of standard buprenorphine hydrochloride (0.02 and 0.04 mg/kg) were tested; the result does not cover repeated dosing, other routes (intramuscular, oral transmucosal), or extended-release formulations. With 14 animals the study could miss a small effect, but the same crossover detected hydromorphone's effect clearly, so a large buprenorphine effect at these doses is unlikely in this model.

Desprez I, Crookes A, Di Girolamo N, Ambros B. Subcutaneous administration of hydromorphone (0.2 mg/kg) provides antinociception in ferrets (Mustela putorius furo). Am J Vet Res. 2023;84(10):1-7. PMID: 37527831. Registry ID: none in the record. MeSH: Animals · Female · Male · Analgesics, Opioid/pharmacology · Anesthesia*/veterinary · Buprenorphine*/pharmacology · Ferrets · Hydromorphone/pharmacology · Cross-Over Studies

Synthesis: one blinded placebo-controlled crossover found no antinociceptive effect of buprenorphine in ferrets; postoperative efficacy versus no analgesia is untested — MAYBE (weak evidence) (the treatment made no difference)

Synthesis

Who: Synthesis of the card above (Desprez 2023, 14 healthy ferrets, thermal nociception crossover) and of the two near-miss records documented in the result, which were fetched at drafting and deliberately not carded as claim-carriers.

Result: (1) Versus no analgesia: Desprez 2023 is the only placebo-controlled record — buprenorphine 0.02 and 0.04 mg/kg subcutaneously did not differ from saline on thermal withdrawal latency over 8 hours, while hydromorphone 0.2 mg/kg did, giving the null an internal positive control. (2) Postoperative evidence without a control group: Plunkard 2024 (PMID: 39164072) developed a ferret pain scoring system and, after ovariohysterectomy, compared a single high dose of extended-release liposomal buprenorphine (Bup-XR, 0.6 mg/kg subcutaneously) with a standard course of buprenorphine hydrochloride (0.02 mg/kg subcutaneously every 10 to 12 hours for 8 doses): Bup-XR ferrets had significantly lower respiratory rate and posture scores in the first 24 hours and were less likely to react to palpation of the incision. Because both groups received buprenorphine, the study supports extended-release over repeated standard dosing, not buprenorphine over no analgesia; its pharmacokinetic arms (n = 4 animals per timepoint) found all tested extended-release doses reached therapeutic plasma levels by 30 minutes, with high-dose Bup-XR maintaining them for 72 hours. (3) Pharmacokinetics only: Ryan 2026 (PMID: 41160983), a randomised crossover in 8 female ferrets, found oral transmucosal and intramuscular buprenorphine 0.04 mg/kg both reached plasma levels the authors call theoretically analgesic — but that judgement uses an effective-concentration figure (0.6 ng/mL) established in DOGS, a cross-species threshold, and the study measured no pain outcome; terminal half-lives were 2.77 hours (intramuscular) and 0.715 hours (oral transmucosal). (4) Design class (a): randomisation and blinding are established by the carded Desprez 2023 record for the buprenorphine-versus-saline comparison in ferrets; the MAYBE (weak evidence) stamp reflects that this is a single small induced-model study and that the clinical postoperative question remains untested against any control.

Watch out: One-home check at drafting: PMID 37527831 does not appear in any other pack on disk, and PMIDs 39164072 and 41160983 are not claim-carriers elsewhere. Records deliberately not carded: Plunkard 2024 (no untreated or placebo arm — a formulation-versus-formulation comparison) and Ryan 2026 (pharmacokinetic study; its analgesia statement borrows a dog plasma threshold and measures no pain outcome — cross-species borrowing this library does not card). A 2022 influenza-pathogenesis study that used buprenorphine treatment in ferrets (PMID: 35256041) is not an analgesia trial and was not used. Practical reading: this shelf does NOT show buprenorphine is useless in ferrets — it shows the standard subcutaneous doses failed the only controlled antinociception test, and that postoperative use currently rests on uncontrolled formulation comparisons and plasma-level reasoning.

Synthesis of Desprez I et al. PMID: 37527831; Plunkard JCM et al. PMID: 39164072; Ryan KM et al. PMID: 41160983. Registry IDs as on the individual cards (none in the records).

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.